tbuckley/cabot-search huggingface dataset:
The Child With Disabling Illness: Principles of Rehabilitation
Authors: Sheldon Berrol
Journal: JAMA (1975)

Dr. Downey has once again filled a major void in medical literature by the introduction of this volume on pediatric rehabilitation. The subjects covered specifically reflect the interest of the authors, but the volume is comprehensive enough to be of major value on a daily basis in clinical medicine. The initial chapter on juvenile rheumatoid arthritis presents an adequate review of the clinical aspects and differential diagnosis. In addition, it shows a common-sense approach to management and maintenance of function, which draws heavily on the involvement of the parents in the daily management of the disabled child. This concept is frequently reflected and emphasized throughout the volume. A team approach that urges consideration of the total needs of the child is emphasized, with specific chapters on dental care, sexuality, and a strong plea for early vocational planning of the handicapped child. In the chapter on spinal injury, one would like
Corticosteroid Bindings.
Authors: W. H. Daughaday
Journal: Annals of Internal Medicine (1963)

s1 April 1963Corticosteroid Bindings.W. H. Daughaday, M.D.W. H. Daughaday, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-58-4-718_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA brief survey will be made of the characteristics of the physicochemical methods that have been used to study the binding of steroid hormones by plasma protein. There is now considerable evidence obtained by several laboratories indicating that 2 plasma proteins are responsible for most of the binding of steroids:1. Albumin is the principal binding protein for the less polar steroids, (androgens, estrogens, and progesterone). Despite its polar characteristic, bound aldosterone of plasma is primarily associated with this protein.2. The corticosteroid binding globulin (CBG), sometimes called "transcortin," is an alpha glycoprotein that has a high affinity for the... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: W. H. Daughaday, M.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1963Volume 58, Issue 4Page: 718-718KeywordsAldosteroneAndrogensBlood plasmaEstrogensGlobulinsGlycoproteinsPlasma proteinsProgesteroneProteinsSteroid hormones ePublished: 1 December 2008 Issue Published: 1 April 1963 PDF downloadLoading ...
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
Authors: Stefan D Anker, Javed Butler, Gerasimos S Filippatos, Waheed Jamal, Afshin Salsali, Janet Schnee, Karen Kimura, Cordula Zeller, Jyothis George, Martina Brueckmann, Faiez Zannad, Milton Packer
Journal: European Journal of Heart Failure (2019)

Background The principal biological processes that characterize heart failure with a preserved ejection fraction (HFpEF) are systemic inflammation, epicardial adipose tissue accumulation, coronary microcirculatory rarefaction, myocardial fibrosis and vascular stiffness; the resulting impairment of left ventricular and aortic distensibility (especially when accompanied by impaired glomerular function and sodium retention) causes increases in cardiac filling pressures and exertional dyspnoea despite the relative preservation of left ventricular ejection fraction. Independently of their actions on blood glucose, sodium–glucose co‐transporter 2 (SGLT2) inhibitors exert a broad range of biological effects (including actions to inhibit cardiac inflammation and fibrosis, antagonize sodium retention and improve glomerular function) that can ameliorate the pathophysiological derangements in HFpEF. Such SGLT2 inhibitors exert favourable effects in experimental models of HFpEF and have been found in large‐scale trials to reduce the risk for serious heart failure events in patients with type 2 diabetes, many of whom were retrospectively identified as having HFpEF. Study design The EMPEROR‐Preserved Trial is enrolling ≈5750 patients with HFpEF (ejection fraction &gt;40%), with and without type 2 diabetes, who are randomized to receive placebo or empagliflozin 10 mg/day, which is added to all appropriate treatments for HFpEF and co‐morbidities. Study aims The primary endpoint is the time‐to‐first‐event analysis of the combined risk for cardiovascular death or hospitalization for heart failure. The trial will also evaluate the effects of empagliflozin on renal function, cardiovascular death, all‐cause mortality and recurrent hospitalization events, and will assess a wide range of biomarkers that reflect important pathophysiological mechanisms that may drive the evolution of HFpEF. The EMPEROR‐Preserved Trial is well positioned to determine if empagliflozin can have a meaningful impact on the course of HFpEF, a disorder for which there are currently few therapeutic options.
Correction: Antitumoral Immune Response by Recruitment and Expansion of Dendritic Cells in Tumors Infected with Telomerase-Dependent Oncolytic Viruses
Journal: Cancer Research (2011)

In this article (Cancer Res 2009;69:1448–58), which was published in the February 15, 2009 issue of Cancer Research (1), there was a typographical error in the first author's name. The correct name should be Ramakrishna Edukulla.
Embryonic Estrogen Receptors: Do They Have a Physiological Function?
Authors: Jack Gorski, Qunfang Hou
Journal: Environmental Health Perspectives (1995)

In normal estrogen target tissues, estrogen action is mediated through a specific nuclear transcription factor, the estrogen receptor (ER).The site of estrogen action in the developing organism is therefore determined by cells that contain ER and other necessary tissue and gene-specific components for estrogen-mediated transcription.Immunocytochemical methods were used to determine the cellular localization and tissue distribution of ERs in reproductive tracts of mouse fetuses.Nuclear staining for ER was observed in reproductive tracts at fetal days 13 to 15. ERs were present in the precursors of both male and female reproductive tracts at these early developmental stages, which may be attributable to their similar embryonic origins.However, as the tissues undergo sexual differentiation at later fetal and early neonatal ages, ER increases in the female reproductive tracts as compared with the male.ER was detected by immunoblotting on fetal day 10 (before sexual differentiation) in extracts of whole mouse embryos.To determine whether ER and progesterone receptor genes are expressed earlier in development, we examined RNA from preimplantation mouse embryos using reverse transcriptase-polymerase chain reaction techniques.ER mRNA was found in oocytes and fertilized eggs.Message concentration declined at the 2-cell stage and reached its lowest level at the 5-to 8-cell stage.ER mRNA was not detectable at the morula stage but reappeared at the blastocyst stage.Progesterone receptor mRNA was not detectable until the blastocyst stage.The embryonic expression of ER and progesterone receptor genes in the blastocyst suggests a possible functional requirement for estrogen and progesterone receptors in preimplantation embryos.
CEREBRAL CYSTS
Authors: WINCHELL McK. CRAIG
Journal: JAMA (1934)

The clinical syndromes produced by intracranial lesions follow fairly definite lines of progression, and may indicate the underlying pathologic changes. However, it is reasonable to assume that a definite pathologic diagnosis can be made only at operation or necropsy. General and neurologic examinations may indicate whether the lesion is primary or secondary, inflammatory or neoplastic, and encephalography or ventriculography may be necessary to assist in localization. When the lesion has been localized and found suitable for operation, it is important to determine whether it is cortical or subcortical, cystic or solid and neoplastic or non-neoplastic. Because of the difficulty in distinguishing between cerebral cysts at the time of operation, we have reviewed the various types for the purpose of comparison. Between 10 and 15 per cent of the surgical conditions of the brain were found to be cystic. This particular group of conditions involving the cerebral hemispheres has been considered
Mucormycotic endocarditis of the pulmonary valve
Authors: M. S. Erdos
Journal: JAMA (1972)

Endocarditis of the pulmonary valve due to<i>Mucor</i>occurred in a 76-year-old man with leukopenia secondary to myelofibrosis and myeloid metaplasia. Postmortem examination revealed a large mycotic vegetation with destruction of the pulmonary valve leaflets, vegetations in the wall of the main pulmonary artery, and mycotic pulmonary embolization with cavitary abscess formation. The clinical course was complicated by disseminated intravascular coagulation. This is the first report, to our knowledge, of infection of the right pulmonary valve and of disseminated intravascular coagulation due to<i>Mucor</i>.
Abstract 4605: Increased Body Mass Index is Protective against Low Bone Mineral Density in Patients with Heart Failure
Authors: Demetrius A Abshire, Debra K Moser, Jody L Clasey, Misook L Chung, Susan J Pressler, Sandra B Dunbar, Seongkum Heo, Terry A Lennie
Journal: Circulation (2008)

Patients with heart failure (HF) may be at greater risk for decreased bone mineral density (BMD) than similarly-aged healthy adults due to limited activity and medications. Being overweight or obese may protect against decreased BMD due to greater weight bearing and hormonal differences. However, these assumptions have never been tested. The purposes were to compare BMD between patients with HF and similarly-aged healthy adults, compare BMD among normal weight, overweight, and obese patients with HF, and determine whether body mass index (BMI) is a predictor of BMD in patients with HF. A total of 119 patients with HF (preserved or non-preserved systolic function, age = 61 ± 12 yrs, 61% NYHA Class III/IV) and 58 community-dwelling older adults free of cardiovascular disease (age = 70 ± 7 yrs) underwent total body dual-energy x-ray absorptiometry scans. Bone mineral density Z-scores (matched for sex, age, weight, and ethnicity) were compared between patients with HF and healthy elders. Patients with HF were divided into four BMI categories to compare differences in total body BMD by BMI. Multiple linear regression was used to test whether BMI predicted BMD in patients with HF after controlling for age, sex, and NYHA class. Patients with HF had lower total body area BMD Z-scores (0.32 ± 1.20) than the healthy elders (0.88 ± 1.30, p = 0.005). Within the HF group, those with a BMI &lt;25 kg/m 2 had lower total body BMD (1.13 ± 0.13 g/cm 2 ) compared to those with BMIs of 25–29.9 kg/m 2+ (1.24 ± 0.13 g/cm 2 , p = 0.002), 30 –34 kg/m 2+ (1.23 ± 0.12 g/cm 2 , p = 0.019), and &gt;34 kg/m 2 (1.26 ± 0.13 g/cm 2 , p &lt; 0.001). In the multiple linear regression, BMI was a significant predictor of BMD in patients with HF (β= 0.337, p &lt; 0.001), explaining an additional 11% of the variance beyond age, sex, and NYHA class (R 2 = 0.40, p &lt;0.001). These results suggest that while HF is associated with decreased BMD, being overweight or obese may be protective against low BMD. This may be another example of better outcomes in overweight and obese patients with HF. This research has received full or partial funding support from the American Heart Association, AHA Great Rivers Affiliate (Delaware, Kentucky, Ohio, Pennsylvania &amp; West Virginia).
Hematology
Authors: W. H. Crosby
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fluorescent Microscopic Examinations of Venous Blood in Traumatic Fat Embolism
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pregnancy Loss in the Antiphospholipid-Antibody Syndrome — A Possible Thrombogenic Mechanism
Authors: Rosalind Cartwright
Journal: New England Journal of Medicine (1997)

evolve a plot by relating them in terms of emotional memory systems.Emotions are the key that unlock particular boxes of images, and the dream is composed by our learned expectations that recombine the elements into something novel, ruled by what belongs together emotionally.Does this answer the problem of dream structure?Not to the satisfaction of the researcher.There is still much to understand about the working of the mind asleep.This book may stimulate some to address this area.In any case, it is one that the intelligent, non-dream professional can read with enjoyment and from it learn how to view dreams in the wider context of creative thinking.
The value of the selenomethionine Se 75 scan in preoperative localization of parathyroid adenomas
Authors: W. DiGiulio
Journal: JAMA (1969)

The selenomethionine Se 75 scan was performed in 42 patients with a clinical diagnosis of hyperparathyroidism. The scan correctly localized the abnormal gland in 13 of 23 patients with proven parathyroid adenoma. The parathyroid scan was not helpful in seven patients with parathyroid hyperplasia. Size was the most important factor contributing to visualization of parathyroid adenomas. Adenomas larger than 2 gm were consistently visualized while those weighing less than 1 gm were commonly not detected by the scan. High background over the mediastinum precludes the possibility of detecting most mediastinal adenomas by this technique. The value of the selenomethionine Se 75 parathyroid scan is thus limited in patients with small adenomas or hyperplastic glands and in patients with adenomas or hyperplastic glands lying deep in the thorax.
Obstetrics-Gynecology
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: BMJ (1944)

MERITISH "Pay as you Earn"A. P. is employed by two authorities, one of which usually pays the fees two or three months after they are earned.In consequence some fees earned before April 5, 1944 (and therefore part of the income already assessed for 1943-4) were paid after that date and suffered deduction of tax under " pay as you earn."Wtat is his remedy?
A BRIEF DIRECTORY OF CHICAGO MEDICAL INSTITUTIONS,Prepared for the convenience of members of the American Medical Association who may visit Chicago.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Varicella Vaccine
Authors: Max Bader
Journal: JAMA (1994)

<h3>To the Editor.</h3> —A vaccine to prevent chickenpox will soon be approved by the Food and Drug Administration for use in the United States. It may be safe and effective for selective use among high-risk children and susceptible adults, especially the immunologically impaired. However, before the vaccine becomes part of the routine childhood immunization package, there must be solid information on the duration and quality of immunity conferred, the effect of the vaccine with respect to later development of herpes zoster, the result of vaccine introduction on the natural transmission of chickenpox, and the availability of the vaccine to all children for whom it is recommended. General use of varicella vaccine by the private sector would probably interfere sufficiently with the natural transmission of chickenpox to cause more teenage and adult cases among the unimmunized who depend on the public sector. That was the experience with mumps vaccine.<sup>1,2</sup>Public
Pharmacologic Approaches to Protection against Radiation-Induced Lethality and Other Damage
Authors: Joseph F. Weiss
Journal: Environmental Health Perspectives (1997)

Studies on mechanisms of radioprotection are leading to a more rational use of protectors for different applications.In considering the feasibility of radioprotectors that act through various mechanisms, it is necessary to distinguish the application needed, e.g., protection against accidental external or internal exposures; acute high-dose radiation injury or low doses over a long period, high-LET radiation exposures during space flight, and protection of normal tissues of cancer patients who are undergoing therapy.Protectors generally are classified as either sulfhydryl compounds, other antioxidants, or receptor-mediated agents (e.g., bioactive lipids, cytokines, and growth factors).This review focuses on comparative radioprotection and toxicity studies in mice using the most effective phosphorothioate agents designated as WR-compounds and other classes of protectors.The superiority of phosphorothioates (WR-2721, WR-1 51327) as radioprotectors appears to be related to their high affinity for DNA and the similarity in structure of phosphorothioate metabolites to polyamines, and their effects on processes related to DNA structure and synthesis.Drug tolerance levels are available from clinical trials using WR-2721 (amifostine) and provide a basis for discussions of the disadvantages of phosphorothioate administration outside a clinical setting.In this regard, arguments are presented against the current use of WR-2721 by Department of Energy personnel for planned radiation exposures during emergencies.Future research may demonstrate, however, that pharmacologic agents could be useful in accident scenarios, especially when used in combination with therapeutic measures.Assessment of potential prophylactic measures should consider compatibility with therapeutic measures currently in use or ones that might be available in the future for the treatment of radiation injuries.These include antiemetics, purified stem cells, granulocyte colony-stimulating factor, and other cytokines.Their potential usefulness against radiation-induced mutagenesis of pre-and postexposure administration of phosphorothioates and other classes of protectors should be corroborated in humans.